ArticleCureus2024

Efficacy and Safety of Bendamustine-Rituximab as Frontline Therapy for Indolent Non-Hodgkin Lymphoma: A Real-World, Single-Center, Retrospective Study.

Tevy Chan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.